Tasos Konidaris - Mar 12, 2024 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President & CFO
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Stock symbol: AMRX
Transactions as of: Mar 12, 2024
Transactions value $: -$163,495
Form type: 4
Date filed: 3/14/2024, 04:17 PM
Previous filing: Mar 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+87.7K	+18.65%		558K	Mar 12, 2024	Direct	F1, F2
transaction	AMRX	Class A Common Stock	Tax liability	-$163K	-30.8K	-5.52%	$5.31	527K	Mar 12, 2024	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-87.7K	-100%	$0.00^*	0	Mar 12, 2024	Class A Common Stock	87.7K		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3	Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4	On March 12, 2020, the reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.